16 Oct 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with advanced solid tumors will be presented at the 2023 European Society for Medical Oncology（ESMO）annual meeting to be held in Spain, from October 20 to 24, 2023. The Irpagratinib BID cohorts demonstrated a promising antitumor activity with an ORR of 40.7% in FGF19+ HCC pts with prior therapies. Both research results will be the first of such release by a Chinese company for the respective target.

16 October 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held in Boston, U.S.. These two research results respectively demonstrate the latest preclinical research progress of the next generation of PRMT5*MTA inhibitors and small molecule brain penetrant PD-L1 inhibitors in Abbisko‘s pipeline. As the world's highest-quality research conference focusing on molecular targeting and tumor treatment, the ENA conference collects the most cutting-edge researches on innovative drugs and therapies in the field of tumor treatment.

25 Sep 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that Irpagratinib (ABSK-011), a highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (“FGFR4”) in patients with advanced hepatocellular carcinoma（HCC）has obtained investigational new drug (IND) approval from the U.S. FDA.

11 September 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as “Abbisko Therapeutics” hereafter) announced that the Europe EMA had approved its CSF-1R inhibitor pimicotinib（ABSK021）for a randomized, double-blind,

2 August 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced first patient dosing of “A Phase 3, Randomized, Double-blind

31 July 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with advanced solid tumors will be presented at the 2023

12 June 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”hereafter) today announced that the first patient has been dosed in the phase II trial evaluating its CSF-1R inhibitor, Pimicotinib (ABSK021), in patients with cGVHD.

7 June 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced that its novel CSF-1R inhibitor Pimicotinib (ABSK021）has been granted the Priority Medicine (PRIME) designation by the European Medicines Agency (EMA) for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery.